>>> US Gapping up

Gapping up
In reaction to earnings/guidance
:

  • BOC +1.8%

Other news:

  • FCNCA +28.7% (purchases Silicon Valley Bridge Bank (SIVB))
  • BLKB +20.2% (Clearlake Capital Group discloses bid to purchase all shares of BLKB for $71/share)
  • BGRY +18.9% (to be acquired by SoftBank Group in go-private transaction)
  • IOVA +9.9% (Completes Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma)
  • NVS +6.5% (reports Kisqali Phase III NATALEE trial meets primary endpoint)
  • FSR +5.9% (achieves longest range of any battery electric SUV sold in Europe)
  • SGFY +5.7% (expects to complete its acquisition of Signify Health (SGFY) on or around March 29, 2023, subject to the satisfaction or waiver of the remaining customary closing conditions set forth in the merger agreement)
  • STKL +4.5% (upgrades To 'B' From 'B-' on improving business and strengthening financial measures; outlook stable)
  • HTGC +3.8% (establishes a new institutional private credit lending program)
  • DIN +3.7% (announces intention to refinance its class A-2-I senior secured notes through a securitization)
  • RPRX +3.7% (announces that the company's Board of Directors has authorized the repurchase of up to $1.0 bln of the company's Class A ordinary shares)
  • ARKO +2.1% (urges Travel Center of America's (TA) Board to consider superior acquisition proposal)
  • RIOT +1.9% (releases investor presentation which includes updates regarding Riot's financial position, business, and operations)
  • COP +1.5% (announces plans to become upstream operator and agreement to purchase additional shareholding interest in APLNG)
  • AZN +1.5% (reports demonstrated sustained benefit in Phase III trial)
  • RIVN +1.2% (moved additional engineers to its EV factory to accelerate output, according to WSJ)
  • WGO +1% (has reached a definitive agreement to acquire Lithionics Battery)

Analyst comments:

  • KEY +7.9% (upgraded to Buy from Neutral at Citigroup)
  • MTB +4.9% (upgraded to Buy from Neutral at Citigroup)
  • PINS +3.9% (upgraded to Buy from Neutral at UBS)
  • ORAN +2.7% (upgraded to Overweight from Equal-Weight at Morgan Stanley)